NCT06015542 - Self-administration of Subcutaneous Elranatamab in the Patients' Homes. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 29, 2025

Primary Completion Date

July 1, 2026

Study Completion Date

July 1, 2027

Conditions

Multiple Myeloma

Interventions

DRUG

Elranatamab

Elranatamab will be administered as monotherapy for six cycles of 28 days. Elranatamab 76 mg will be administered QW with a 2-step-up priming dose regimen administered during the first week (12 mg D1 and 32 mg D4).

Trial Locations (1)

5000

RECRUITING

Odense University Hospital, Odense